- sodium cromoglicate
POM: Prescription only medicine
This information is intended for use by health professionals
Nalcrom 100 mg Capsules
The active component per capsule is:
Sodium Cromoglicate 100.0 mg
For a full list of excipients, see section 6.1.
Hard gelatin capsule with a clear cap and body, marked 'SODIUM CROMOGLICATE 100 mg' in black and containing a white powder.
Nalcrom is indicated for food allergy (where adequate investigations have been performed to determine sensitivity to one or more ingested allergens) in conjunction with restriction of main causative allergens.
Nalcrom must be administered orally.
Adults (including the elderly)
Initial dose: 2 capsules four times daily before meals
Children (2 - 14 years)
Initial dose: 1 capsule four times daily before meals
For adults (including the elderly) and children, if satisfactory control is not achieved within two to three weeks, the dosage may be doubled but should not exceed 40 mg/kg/day.
Maintenance dose: Once a therapeutic response has been achieved, the dose may be reduced to the minimum required to maintain the patient free from symptoms.
Nalcrom is contraindicated in patients with a known hypersensitivity to sodium cromoglicate or to any of the excipients listed in section 6.1.
As with all medication caution should be exercised especially during the first trimester of pregnancy. Cumulative experience with sodium cromoglicate suggests that it has no adverse effects on fetal development. It should only be used in pregnancy where there is a clear need.
It is not known whether sodium cromoglicate is excreted in the breast milk but on the basis of its physico-chemical properties this is considered unlikely. There is no information to suggest that the use of sodium cromoglicate has any undesirable effects on the baby.
Nausea, skin rashes and joint pains have been reported in a few cases.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
As Nalcrom is only absorbed to a minimum extent, no action other than medical supervision should be necessary.
Pharmacotherapeutic group: Antiallergic agents, excluding corticosteroids, ATC Code: A07EB01
Sodium cromoglicate inhibits the release from mast cells of mediators of the allergic reaction. In gastrointestinal allergy the release of mediators can result in gastrointestinal symptoms or may allow absorption of antigenic material leading to systemic allergic reactions.
Animal studies have shown that sodium cromoglicate has a very low order of local or systemic toxicity.
No 2 hard gelatin capsules
Black ink containing:
Iron oxide black (E172)
Store below 25°C. Store in a dry place. Keep the bottle tightly closed in order to protect from moisture.
An aluminium can with aluminium screw cap containing 100 capsules or an HDPE bottle with screw cap containing 100 capsules.
Not all pack sizes may be marketed.
Instructions for use are supplied with each pack.
Aventis Pharma Limited
410 Thames Valley Park Drive
410 Thames Valley Park Drive
1st May 2005
Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
+44 (0)845 372 7101
+44 (0)845 023 0441